# Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Study · id `cardio:ct-nct04373967` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04373967](<https://clinicaltrials.gov/study/NCT04373967>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04373967

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 424 participants.

## Technical summary

Registry record NCT04373967. Randomized; no masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2021-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 424 participants (planned count; ClinicalTrials.gov record NCT04373967, source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)
- Started: 2020-04-29 (actual) (ClinicalTrials.gov record NCT04373967, source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)
- Primary completion: 2021-12-01 (anticipated) (ClinicalTrials.gov record NCT04373967, source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)
- Completion: 2021-12-02 (anticipated) (ClinicalTrials.gov record NCT04373967, source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04373967, source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04373967-2020-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Victoza®.
- Intervention (Drug): Metformin Hydrochloride
- Intervention (Drug): TQZ2451
- Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (`cardio:org-chia-tai-tianqing-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: d13073b0f3e7646487287973468b17de60c8b53a8cc63a4e2f5d6f043d14a305
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
